Skip to main content
Fig. 4 | Acta Neuropathologica Communications

Fig. 4

From: Intravitreal MPTP drives retinal ganglion cell loss with oral nicotinamide treatment providing robust neuroprotection

Fig. 4

Intravitreal MPTP administration does not drive an early retinal neuroinflammatory phenotype. A Microglia were labelled with anti-IBA1, astrocytes and Müller cells with anti-GFAP and Müller cells with anti-GS in retina cross-sections. B For IBA1, GFAP and GS, there were no significant differences in percentage coverage of the inner retina between the vehicle control (green) and 5 mg/mL MPTP (orange) or 50 mg/mL MPTP (red). Scale bar = 100 µm

Back to article page